Therapeutics based on CRISPR genome editing started making their way into human trials about a year ago. However, until recently, scientists still had a limited ability to assess which unintended genome edits accompany the precision genomic cuts characteristic of CRISPR.

Despite advances in genomics and personalized medicine, identifying the best treatment for an individual cancer patient remains challenging. San Francisco-based startup Notable Labs Inc. has developed an approach that aims to improve those odds. Its AI-based platform tests a patient blood sample against hundreds of individual drugs and drug combinations in the lab to help identify the best treatment options for that patient.